C-reactive protein relaxes human vessels in vitro

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 11, 2002, Pages 1865-1868

  Sternik, Leonid ^a   Samee, Saquib ^a   Schaff, Hartzel V ^a   Zehr, Kenton J ^a   Lerman, Lilach O ^a   Holmes, David R ^a   Herrmann, Joerg ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

Author keywords

Atherosclerosis; C reactive protein; Inflammation; Potassium channels; Vasorelaxation

Indexed keywords

BARIUM CHLORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; GLIBENCLAMIDE; NITRIC OXIDE SYNTHASE INHIBITOR; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHLORIDE; TETRYLAMMONIUM CHLORIDE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; INTERNAL MAMMARY ARTERY; MALE; PRIORITY JOURNAL; VASODILATATION;

AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CHLORIDE CHANNELS; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MAMMARY ARTERIES; MIDDLE AGED; POTASSIUM CHANNELS; VASODILATION;

EID: 0036845090     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000033821.96354.90     Document Type: Article

References (25)

1. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763-771.
2. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation. 1999;100:96-102.
3. Rifai N, Ridker PM. High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease. Clin Chem. 2001;47:403-411.
4. Yeh ET, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: Linking inflammation to cardiovascular complications. Circulation. 2000;104:974-975.
5. Volanakis JE. Human C-reactive protein: Expression, structure, and function. Mol Immunol. 2001;38:189-197.
6. Du Clos TW. Function of C-reactive protein. Ann Med. 2000;32:274-278.
7. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386-1392.
8. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: Binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol. 1999;19:2348-2354.
9. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology. 1999;42:23-30.
10. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:2094-2099.
11. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168.
12. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531-2534.
13. Izhar U, Hasdai D, Richardson DM, Cohen P, Lerman A. Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro. Coron Artery Dis. 2000;11:69-76.
14. Hasdai D, Rizza RA, Holmes DR Jr, Richardson DM, Cohen P, Lerman A. Insulin and insulin-like growth factor-I cause coronary vasorelaxation in vitro. Hypertension. 1998;32:228-334.
15. Mathew V, Lerman A. Altered effects of potassium channel modulation in the coronary circulation in experimental hypercholesterolemia. Atherosclerosis. 2001;154:329-335.
16. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated lowdensity lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation. 2001;103:1194-1197.
17. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond). 2000;98:531-535.
18. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zether AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000;102:1000-1006.
19. Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS, Chiariello L, Gioffre PA. Unstable angina and elevated c-reactive protein levels predict enhanced vasoreactivity of the culprit lesion. Circulation. 2001;104:1471-1476.
20. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, Donald AE, Palacios M, Griffin GE, Deanfield JE, MacAllister RJ, Vallance P. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation. 2000;102:994-999.
21. Williams TJ. Oedema and vasodilatation in inflammation: The relevance of prostaglandins. Postgrad Med J. 1977;53:660-662.
22. Raud J. Vasodilatation and inhibition of mediator release represent two distinct mechanisms for prostaglandin modulation of acute mast cell-dependent inflammation. Br J Pharmacol. 1990;99:449-454.
23. Stefanadis C, Diamantopoulos L, Dernellis J, Economou E, Tsiamis E, Toutouzas K, Vlachopoulos C, Toutouzas P. Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. J Mol Cell Cardiol. 2000;32:43-52.
24. Brayden JE, Nelson MT. Regulation of arterial tone by activation of calcium-dependent potassium channels. Science. 1992;256:532-535.
25. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol. 1995;268:C799-C822.